Invasive Pulmonary Aspergillosis Diagnosed by Molecular Test
By LabMedica International staff writers Posted on 12 Jun 2019 |

Image: The PLATELIA ASPERGILLUS Ag Test (Photo courtesy of Bio-Rad Laboratories).
Invasive aspergillosis (IA) is a common opportunistic fungal infection, mainly affecting patients with severe and prolonged neutropenia. Early diagnosis of invasive pulmonary aspergillosis (IPA) is notoriously difficult, but crucial for prompt treatment initiation required to improve patient outcome.
The mycological evidence used for the diagnosis of probable IPA includes traditional microbiological microscopy and culture of a respiratory specimen, along with non-culture-based serological tests, like that of GM antigen in serum and bronchoalveolar lavage (BAL) fluid, as well as β-d-Glucan in serum.
Medical scientists from Rambam Health Care Campus (Haifa, Israel) and their associates performed bronchoscopies using a fiber-optic bronchoscope with cardiopulmonary monitoring. The procedure was conducted under conscious sedation and local anesthesia. Laboratory analysis of the broncho-alveolar lavage (BAL) fluid included the following: cytological staining for the detection of fungal elements, Pneumocystis jirovecii (PJ) bodies and viral inclusion bodies in alveolar cells; bacterial stains and cultures including specific growth media for Mycobacterial spp., Legionella spp.; fungal cultures; viral cultures for herpes simplex virus (HSV), and cytomegalovirus (CMV); polymerase chain reaction (PCR) for the detection of Aspergillus spp., Legionella spp., Mycobacterial spp., PJ, HSV, CMV and respiratory viruses (influenza, parainfluenza, respiratory syncytial virus, adenovirus, human metapneumovirus) nucleic acid.
The GM antigen in serum and BAL fluid was measured using ELISA. Total DNA was prepared from 5 mL of a BAL fluid sample using QIAamp DNA mini kit and was PCR-amplified using a two-step (nested) PCR assay that specifically amplifies a highly conserved Aspergillus species-specific region of the 18S ribosomal RNA gene. A 232bp PCR fragment encoded by the human β-globin gene was amplified in parallel as a control for the presence of host DNA. Total DNA products were amplified in a T3 Thermocycler.
During the 12-year study period, January 2005 to December 2016, 1,072 patients underwent 1,248 bronchoscopies with BAL for a suspected opportunistic lung infection. Of the study population, 630/1072 (59%) were males; median age was 55 (1–90) years. Hematological malignancy was found in 77%, of them 40% had AML and 35.6% underwent hematopoietic stem cell transplantation (HSCT). IPA was diagnosed in 531 patients (42.5%), seven-proven, 280-probable and 244-possible. PCR was positive in 266 cases, of them 213 had IPA, indicating a true positive rate of 80% (213/266) and a false positive rate of 20% (53/266). These results establish the diagnostic performance of PCR to have sensitivity of 40%, specificity of 93%, PPV- 80% and NPV-68%. Of 244 patients with possible IPA, 80 had positive PCR. Including PCR in the diagnostic criteria would move 80 cases from the possible group to the probable one. A combination of positive PCR and/or BAL-GM increases sensitivity to 74%, while positivity of both tests elevates PPV to 99.4%.
The authors concluded that including PCR test for the detection of Aspergillus DNA in BAL in the mycological criteria of the EORTC/MSG definitions increases the rate and the certainty of IPA diagnosis. The study was published in the June 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Rambam Health Care Campus
The mycological evidence used for the diagnosis of probable IPA includes traditional microbiological microscopy and culture of a respiratory specimen, along with non-culture-based serological tests, like that of GM antigen in serum and bronchoalveolar lavage (BAL) fluid, as well as β-d-Glucan in serum.
Medical scientists from Rambam Health Care Campus (Haifa, Israel) and their associates performed bronchoscopies using a fiber-optic bronchoscope with cardiopulmonary monitoring. The procedure was conducted under conscious sedation and local anesthesia. Laboratory analysis of the broncho-alveolar lavage (BAL) fluid included the following: cytological staining for the detection of fungal elements, Pneumocystis jirovecii (PJ) bodies and viral inclusion bodies in alveolar cells; bacterial stains and cultures including specific growth media for Mycobacterial spp., Legionella spp.; fungal cultures; viral cultures for herpes simplex virus (HSV), and cytomegalovirus (CMV); polymerase chain reaction (PCR) for the detection of Aspergillus spp., Legionella spp., Mycobacterial spp., PJ, HSV, CMV and respiratory viruses (influenza, parainfluenza, respiratory syncytial virus, adenovirus, human metapneumovirus) nucleic acid.
The GM antigen in serum and BAL fluid was measured using ELISA. Total DNA was prepared from 5 mL of a BAL fluid sample using QIAamp DNA mini kit and was PCR-amplified using a two-step (nested) PCR assay that specifically amplifies a highly conserved Aspergillus species-specific region of the 18S ribosomal RNA gene. A 232bp PCR fragment encoded by the human β-globin gene was amplified in parallel as a control for the presence of host DNA. Total DNA products were amplified in a T3 Thermocycler.
During the 12-year study period, January 2005 to December 2016, 1,072 patients underwent 1,248 bronchoscopies with BAL for a suspected opportunistic lung infection. Of the study population, 630/1072 (59%) were males; median age was 55 (1–90) years. Hematological malignancy was found in 77%, of them 40% had AML and 35.6% underwent hematopoietic stem cell transplantation (HSCT). IPA was diagnosed in 531 patients (42.5%), seven-proven, 280-probable and 244-possible. PCR was positive in 266 cases, of them 213 had IPA, indicating a true positive rate of 80% (213/266) and a false positive rate of 20% (53/266). These results establish the diagnostic performance of PCR to have sensitivity of 40%, specificity of 93%, PPV- 80% and NPV-68%. Of 244 patients with possible IPA, 80 had positive PCR. Including PCR in the diagnostic criteria would move 80 cases from the possible group to the probable one. A combination of positive PCR and/or BAL-GM increases sensitivity to 74%, while positivity of both tests elevates PPV to 99.4%.
The authors concluded that including PCR test for the detection of Aspergillus DNA in BAL in the mycological criteria of the EORTC/MSG definitions increases the rate and the certainty of IPA diagnosis. The study was published in the June 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Rambam Health Care Campus
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Oral Swab Test to Increase Chances of Pregnancy in IVF
Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more